Selecta Biosciences Inc
SELB
Get informed when a big investor buys or sells
+ FollowMarket Cap$135.2M
Close$
Share Statistics
| Market cap | $135.20 Million |
|---|---|
| Enterprise Value | $28.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.02 |
| Beta | 0.83 |
| Outstanding Shares | 26,855,158 |
Return
| Return on Equity | 102.47% |
|---|---|
| Return on Assets | -52.63% |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.16 |
|---|---|
| PEG | -0.13 |
| Price to Sales | - |
| Price to Book Ratio | -0.15 |
| Enterprise Value to Revenue | 16.01 |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.42 |
| Debt to Equity | -0.08 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
April 30, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Selecta Biosciences Inc
44 employees
CEO: Carsten Brunn Selecta Biosciences Inc. is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic protei...